Your browser doesn't support javascript.
A booster dose of Delta × Omicron hybrid mRNA vaccine produced broadly neutralizing antibody against Omicron and other SARS-CoV-2 variants.
Lee, I-Jung; Sun, Cheng-Pu; Wu, Ping-Yi; Lan, Yu-Hua; Wang, I-Hsuan; Liu, Wen-Chun; Yuan, Joyce Pei-Yi; Chang, Yu-Wei; Tseng, Sheng-Che; Tsung, Szu-I; Chou, Yu-Chi; Kumari, Monika; Lin, Yin-Shiou; Chen, Hui-Feng; Chen, Tsung-Yen; Lin, Chih-Chao; Chiu, Chi-Wen; Hsieh, Chung-Hsuan; Chuang, Cheng-Ying; Cheng, Chao-Min; Lin, Hsiu-Ting; Chen, Wan-Yu; Hsu, Fu-Fei; Hong, Ming-Hsiang; Liao, Chun-Che; Chang, Chih-Shin; Liang, Jian-Jong; Ma, Hsiu-Hua; Chiang, Ming-Tsai; Liao, Hsin-Ni; Ko, Hui-Ying; Chen, Liang-Yu; Ko, Yi-An; Yu, Pei-Yu; Yang, Tzu-Jing; Chiang, Po-Cheng; Hsu, Shang-Te; Lin, Yi-Ling; Lee, Chong-Chou; Wu, Han-Chung; Tao, Mi-Hua.
  • Lee IJ; Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan.
  • Sun CP; Graduate Institute of Microbiology, College of Medicine, National Taiwan University, Taipei, Taiwan.
  • Wu PY; Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan.
  • Lan YH; Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan.
  • Wang IH; Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan.
  • Liu WC; Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan.
  • Yuan JP; Biomedical Translation Research Center, Academia Sinica, Taipei, Taiwan.
  • Chang YW; Biomedical Translation Research Center, Academia Sinica, Taipei, Taiwan.
  • Tseng SC; Biomedical Translation Research Center, Academia Sinica, Taipei, Taiwan.
  • Tsung SI; Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan.
  • Chou YC; Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan.
  • Kumari M; Graduate Institute of Microbiology, College of Medicine, National Taiwan University, Taipei, Taiwan.
  • Lin YS; Biomedical Translation Research Center, Academia Sinica, Taipei, Taiwan.
  • Chen HF; Institute of Cellular and Organismic Biology, Academia Sinica, Taipei, Taiwan.
  • Chen TY; Biomedical Translation Research Center, Academia Sinica, Taipei, Taiwan.
  • Lin CC; Biomedical Translation Research Center, Academia Sinica, Taipei, Taiwan.
  • Chiu CW; Biomedical Translation Research Center, Academia Sinica, Taipei, Taiwan.
  • Hsieh CH; Biomedical Translation Research Center, Academia Sinica, Taipei, Taiwan.
  • Chuang CY; Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan.
  • Cheng CM; Department of Clinical Laboratory Science and Medical Biotechnology, National Taiwan University, Taipei, Taiwan.
  • Lin HT; Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan.
  • Chen WY; Department of Clinical Laboratory Science and Medical Biotechnology, National Taiwan University, Taipei, Taiwan.
  • Hsu FF; Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan.
  • Hong MH; Biomedical Translation Research Center, Academia Sinica, Taipei, Taiwan.
  • Liao CC; Institute of Cellular and Organismic Biology, Academia Sinica, Taipei, Taiwan.
  • Chang CS; Institute of Cellular and Organismic Biology, Academia Sinica, Taipei, Taiwan.
  • Liang JJ; Biomedical Translation Research Center, Academia Sinica, Taipei, Taiwan.
  • Ma HH; Institute of Cellular and Organismic Biology, Academia Sinica, Taipei, Taiwan.
  • Chiang MT; Biomedical Translation Research Center, Academia Sinica, Taipei, Taiwan.
  • Liao HN; Institute of Cellular and Organismic Biology, Academia Sinica, Taipei, Taiwan.
  • Ko HY; Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan.
  • Chen LY; Biomedical Translation Research Center, Academia Sinica, Taipei, Taiwan.
  • Ko YA; Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan.
  • Yu PY; Genomics Research Center, Academia Sinica, Taipei, Taiwan.
  • Yang TJ; Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan.
  • Chiang PC; Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan.
  • Hsu ST; Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan.
  • Lin YL; Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan.
  • Lee CC; Biomedical Translation Research Center, Academia Sinica, Taipei, Taiwan.
  • Wu HC; Institute of Biological Chemistry, Academia Sinica, Taipei, Taiwan.
  • Tao MH; Institute of Biological Chemistry, Academia Sinica, Taipei, Taiwan.
J Biomed Sci ; 29(1): 49, 2022 Jul 07.
Article in English | MEDLINE | ID: covidwho-1923546
ABSTRACT

BACKGROUND:

With the continuous emergence of new SARS-CoV-2 variants that feature increased transmission and immune escape, there is an urgent demand for a better vaccine design that will provide broader neutralizing efficacy.

METHODS:

We report an mRNA-based vaccine using an engineered "hybrid" receptor binding domain (RBD) that contains all 16 point-mutations shown in the currently prevailing Omicron and Delta variants.

RESULTS:

A booster dose of hybrid vaccine in mice previously immunized with wild-type RBD vaccine induced high titers of broadly neutralizing antibodies against all tested SARS-CoV-2 variants of concern (VOCs). In naïve mice, hybrid vaccine generated strong Omicron-specific neutralizing antibodies as well as low but significant titers against other VOCs. Hybrid vaccine also elicited CD8+/IFN-γ+ T cell responses against a conserved T cell epitope present in wild type and all VOCs.

CONCLUSIONS:

These results demonstrate that inclusion of different antigenic mutations from various SARS-CoV-2 variants is a feasible approach to develop cross-protective vaccines.
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Randomized controlled trials Topics: Vaccines / Variants Limits: Animals / Humans Language: English Journal: J Biomed Sci Journal subject: Medicine Year: 2022 Document Type: Article Affiliation country: S12929-022-00830-1

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Randomized controlled trials Topics: Vaccines / Variants Limits: Animals / Humans Language: English Journal: J Biomed Sci Journal subject: Medicine Year: 2022 Document Type: Article Affiliation country: S12929-022-00830-1